Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | CD274 negative |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04356729 | Phase II | Atezolizumab + Bevacizumab | A Phase II Trial of PD-L1 Therapy Combined with Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | Active, not recruiting | USA | 0 |
| NCT07299409 | Phase II | Sacituzumab govitecan-hziy | First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. | Not yet recruiting | CAN | 0 |
| NCT05491226 | Phase II | Axatilimab + Pembrolizumab | Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation | Active, not recruiting | USA | 0 |
| NCT04468061 | Phase II | Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Recruiting | USA | 0 |
| NCT04837209 | Phase II | Dostarlimab-gxly + Niraparib | Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR) | Active, not recruiting | USA | 0 |